Skip to main content
Fig. 1 | BMC Endocrine Disorders

Fig. 1

From: Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin

Fig. 1

Changes in GC dose and body weight at pretreatment and discharge. a Timing of data collection, and treatment course of non-Dula and Dula groups in this study. b GC maintenance dose at pretreatment and discharge, and (c) cumulative GC dose during the observation. d Bodyweight changes at pretreatment and discharge. Data are expressed as Tukey’s box-and-whisker plots. Pre, pretreatment. GC, glucocorticoid. *** p < 0.001 vs. pretreatment of the same group.

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us